MLTX — MoonLake Immunotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.53bn
- $2.09bn
- 35
- 22
- 28
- 18
Annual income statement for MoonLake Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 53.6 | 65.1 | 54.1 | 143 |
| Operating Profit | -53.6 | -65.1 | -54.1 | -143 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -53.6 | -64.5 | -44 | -121 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -53.6 | -64.5 | -44.1 | -121 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -53.6 | -50 | -36 | -119 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -53.6 | -50 | -36 | -119 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.45 | -1.7 | -0.733 | -1.89 |